Alzheimer disease
LG Apostolova - Continuum: Lifelong Learning in Neurology, 2016 - journals.lww.com
Abstract Purpose of Review: This article discusses the recent advances in the diagnosis and
treatment of Alzheimer disease (AD). Recent Findings: In recent years, significant advances …
treatment of Alzheimer disease (AD). Recent Findings: In recent years, significant advances …
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
K Blennow, H Hampel, M Weiner… - Nature Reviews …, 2010 - nature.com
Intense multidisciplinary research has provided detailed knowledge of the molecular
pathogenesis of Alzheimer disease (AD). This knowledge has been translated into new …
pathogenesis of Alzheimer disease (AD). This knowledge has been translated into new …
A parameter-efficient deep learning approach to predict conversion from mild cognitive impairment to Alzheimer's disease
Some forms of mild cognitive impairment (MCI) are the clinical precursors of Alzheimer's
disease (AD), while other MCI types tend to remain stable over-time and do not progress to …
disease (AD), while other MCI types tend to remain stable over-time and do not progress to …
Cerebrospinal fluid levels ofβ-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia
P Buchhave, L Minthon, H Zetterberg… - Archives of general …, 2012 - jamanetwork.com
Context Early detection of prodromal Alzheimer disease (AD) is important because new
disease-modifying therapies are most likely to be effective when initiated during the early …
disease-modifying therapies are most likely to be effective when initiated during the early …
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment
Context Small single-center studies have shown that cerebrospinal fluid (CSF) biomarkers
may be useful to identify incipient Alzheimer disease (AD) in patients with mild cognitive …
may be useful to identify incipient Alzheimer disease (AD) in patients with mild cognitive …
CSF markers for incipient Alzheimer's disease
K Blennow, H Hampel - The Lancet Neurology, 2003 - thelancet.com
Early diagnosis of Alzheimer's disease (AD) is needed to initiate symptomatic treatment with
acetylcholinesterase inhibitors, and will be of even greater significance if drugs aimed at …
acetylcholinesterase inhibitors, and will be of even greater significance if drugs aimed at …
[HTML][HTML] Biomarkers for the early detection and progression of Alzheimer's disease
The recent failures of potential disease-modifying drugs for Alzheimer's disease (AD) may
reflect the fact that the enrolled participants in clinical trials are already too advanced to …
reflect the fact that the enrolled participants in clinical trials are already too advanced to …
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the …
Background Alzheimer's disease (AD) pathology is common in patients with amnestic mild
cognitive impairment (aMCI) without dementia, but the prevalence of AD pathology in …
cognitive impairment (aMCI) without dementia, but the prevalence of AD pathology in …
The cerebrospinal fluid “Alzheimer profile”: easily said, but what does it mean?
FH Duits, CE Teunissen, FH Bouwman, PJ Visser… - Alzheimer's & …, 2014 - Elsevier
Background We aimed to identify the most useful definition of the “cerebrospinal fluid
Alzheimer profile,” based on amyloid-ß 1-42 (Aβ 42), total tau, and phosphorylated tau (p …
Alzheimer profile,” based on amyloid-ß 1-42 (Aβ 42), total tau, and phosphorylated tau (p …
Total and phosphorylated tau protein as biological markers of Alzheimer's disease
H Hampel, K Blennow, LM Shaw, YC Hoessler… - Experimental …, 2010 - Elsevier
Advances in our understanding of tau-mediated neurodegeneration in Alzheimer's disease
(AD) are moving this disease pathway to center stage for the development of biomarkers …
(AD) are moving this disease pathway to center stage for the development of biomarkers …